Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2027

Conditions
Systemic Sclerosis (SSc)Scleroderma
Interventions
BIOLOGICAL

Tibulizumab

Anti BAFF/IL-17 antibody

OTHER

Placebo

Placebo (inactive)

Trial Locations (19)

11000

RECRUITING

Institute of Rheumatology - PPDS, Belgrade

33324

RECRUITING

IRIS Research and Development LLC, Plantation

48109

RECRUITING

University of Michigan Hospital, Ann Arbor

52242

RECRUITING

University of Iowa, Iowa City

76012

RECRUITING

Rheumatology Associates, Arlington

92037

RECRUITING

UCSD Altman Clinical and Translational Research Institute Center for Clinical Research, La Jolla

C1023

RECRUITING

STAT Research S.A., Buenos Aires

T4000AXL

RECRUITING

Centro de Investigaciones Médicas Tucumán, San Miguel de Tucumán

C1015

RECRUITING

Organización Médica de Investigación, Buenos Aires

C1061

RECRUITING

Centro de Investigación y Prevención Cardiovascular-Arenales, Buenos Aires

C1405BFN

RECRUITING

Instituto de Investigación Clínica TyT, Buenos Aires

C1426ABP

RECRUITING

Centro Medico de Estudios Clinicos y Farmacovigilancia (CECYF), Buenos Aires

C1426

RECRUITING

Consultorios Médicos Dr. Doreski, Buenos Aires

AB25 2ZN

RECRUITING

Aberdeen Royal Infirmary, Aberdeen

BA1 3NG

RECRUITING

Royal National Hospital for Rheumatic Diseases, Bath

DD2 1SG

RECRUITING

Ninewells Hospital, Dundee

L9 7AL

RECRUITING

Aintree University Hospital, Liverpool

NW3 2QG

RECRUITING

Royal Free Hospital, London

ST6 7AG

RECRUITING

Haywood Community Hospital, Stoke-on-Trent

All Listed Sponsors
lead

Zura Bio Inc

INDUSTRY

NCT06843239 - Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | Biotech Hunter | Biotech Hunter